Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: Mild‐Alzheimer's disease (AD) subjects without significant Aβ pathology represent a confounding finding for clinical trials because they may not progress clinically on the expected trajectory, adding variance into analyses where slowing of progression is being measured. Methods: A prediction model based on structural magnetic resonance imaging (MRI) in combination with baseline demographics and clinical measurements was used to impute Aβ status of a placebo‐treated mild‐AD sub‐cohort (N = 385) of patients participating in global phase 3 trials. The clinical trajectories of this cohort were evaluated over 18 months duration of the trial, stratified by imputed Aβ status within a mixed‐model repeated measures statistical framework. Results: In the imputed Aβ‐positive cohort, both cognitive (ADAS‐Cog 14 and MMSE) and functional (ADCS‐iADL) measures declined more rapidly than in the undifferentiated population. Discussion: Our results demonstrate imputing Aβ status from MRI scans in mild‐AD subjects may be a useful screening tool in global clinical trials if amyloid measurement is not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“The second possible interpretation, not mutually exclusive, comes from pathologic studies, especially those of Braak et al. [37,38], showing that during the development of AD pathology, tau tangles increase, associated with synapse loss and neurodegeneration, while at the same time, widespread…”
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The “A b hypothesis” [35,36] posits that accumulation of A b is primarily responsible for the accumulation of tau tangles, synaptic dysfunction, neurodegeneration, and cognitive decline especially in memory function, which characterizes AD.”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Analysis of A b biomarker subgroups in phase 3 clinical trials from two independent drug development programs revealed that approximately 27% of subjects meeting clinical inclusion criteria for mild-AD were A b -negative [4,5].”
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“In contrast, magnetic resonance imaging (MRI) is more widely available and typically already included in clinical trial protocols for radiologic monitoring [6].”
Self-citationRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“A PiB cutoff of 1.47 from the study of Jagust et al. [14] was applied to identify PiB-negative ADNI CN subjects.”
InfluentialSelf-citationRelationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 1×
“Analysis of A b biomarker subgroups in phase 3 clinical trials from two independent drug development programs revealed that approximately 27% of subjects meeting clinical inclusion criteria for mild-AD were A b -negative [4,5].”
Self-citationBourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918b5 · Cited by 220 · cited 2×
“Both positron emission tomography (PET) imaging, using A b -specific radiotracers such as [ 11 C]-PIB or [ 18 F]-florbetapir, and measurement of A b proteins from cerebral spinal fluid (CSF) samples, are widely used in the research setting to quantify brain A b plaque load.”
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
AV45-A11 Study Group, Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.9 · Cited by 195 · cited 4×
“In contrast, people with positive Ab scans declined, with MMSE scores diverging significantly from Ab negatives at 6 months, and ADAS-Cog11 scores at 24 months [39], similar to what we observed in these global clinical trial data (Figs.”
Influential
Cited by
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.005 · Cited by 454
Self-citationNovak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187
Self-citationPredicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
“) to predict which clinically screened participants are likely to have abnormal amyloid levels (Mielke et al., 2012; Tosun et al., 2016).”
BackgroundSalvatore, C., Cerasa, A., & Castiglioni, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00135 · Cited by 78
Metadata
- Authors
- Tosun, D., Chen, Y.-F., Yu, P., Sundell, K. L., Suhy, J., Siemers, E., Schwarz, A. J., Weiner, M. W., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-04-21
- Volume
- 12
- Issue
- 9
- Pages
- 977-986
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2339392274
- Cited by
- 27
- References
- 9
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. https://app.cochat.ai/papers/10.1016/j.jalz.2016.03.009
- The paper
- Tosun, D., Chen, Y.-F., Yu, P., Sundell, K. L., Suhy, J., Siemers, E., Schwarz, A. J., Weiner, M. W., & Initiative, A. D. N. (2016). Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.03.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.